Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
合伙人律师
Pirozzolo, Jack W.
合伙人律师

Related Blogs

Capabilities

Suggested News & Insights

TX AG’s Office Continues Aggressive Enforcement Against Healthcare Entities Operating in TexasFebruary 25, 2026
Original Source
DAAG Brenna Jenny Warns Heightened FCA Enforcement Is “The New Normal,” Addresses Enforcement Priorities and PoliciesFebruary 20, 2026
Original Source
DAAG Jenny Reinforces Commitment to FCA Enforcement Premised on “Unlawful DEI”February 20, 2026
Original Source
DOJ Attorneys Underscore Heightened Focus on Trade Fraud During the Annual Qui Tam ConferenceFebruary 19, 2026
Original Source
Drug Pricing and Medicaid Rebate Reporting: Enforcement Risk RemainsFebruary 17, 2026
Reuters
OIG Releases Long-Awaited Medicare Advantage Compliance Program GuidanceFebruary 10, 2026
Global Life Sciences Update